Product DevelopmentCerus landed CE Mark for its next-generation Illuminator well ahead of expectations, marking a source of upside to guidance.
ProfitabilityCerus delivered positive adjusted EBITDA of $5.7M for the full year, indicating a productive quarter from a profitability standpoint.
Regulatory ProgressTUV-SUD completed review of the INTERCEPT RBC clinical module, expanding its CE Mark submission to all patient indications, signaling positive momentum in securing regulatory clearance.
Revenue GrowthStrength in North America and IFC propelled Cerus to 13% revenue growth.